Nov 09, 2022 4:15pm EST DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results
Nov 07, 2022 8:32am EST DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022
Oct 31, 2022 8:32am EDT DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference
Sep 14, 2022 8:30am EDT DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations
Sep 06, 2022 4:10pm EDT DiaMedica Therapeutics to Present at Lake Street’s 6th Annual Best Ideas Growth Conference
Aug 10, 2022 5:20pm EDT DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results
Aug 04, 2022 8:12am EDT DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022
Aug 01, 2022 4:32pm EDT DiaMedica Therapeutics to Participate in the BTIG Biotechnology Conference 2022
Jul 06, 2022 4:41pm EDT DiaMedica Therapeutics Announces Clinical Hold of its Phase 2/3 ReMEDy2 Clinical Trial for DM199
